The total return over the past 12 months is +96.11% vs. +16.94% for the S&P 500. So far it's up +30.80% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +96.11% | (3.16%) | +29.93% | N/A | N/A | N/A |
| Total Return CAGR | +96.11% | (3.16%) | +29.93% | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Immunovant, Inc. (IMVT)
| Year | Start price | End price | IMVT Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $25.42 | $33.25 | +30.80% | +14.51% | +16.29% |
| 2025 | $24.77 | $25.42 | +2.62% | +17.72% | (15.10%) |
| 2024 | $42.13 | $24.77 | (41.21%) | +24.89% | (66.10%) |
| 2023 | $17.75 | $42.13 | +137.35% | +26.19% | +111.16% |
| 2022 | $8.52 | $17.75 | +108.33% | (18.17%) | +126.50% |
| 2021 | $46.19 | $8.52 | (81.55%) | +28.74% | (110.29%) |
| 2020 | $15.87 | $46.19 | +191.05% | +18.37% | +172.68% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
